| Document |
Document Title |
|
WO/2024/079311A1 |
The present invention relates to the field of immunology. In particular, it relates to novel long cysteine-containing immunogenic peptides, wherein the cysteine has been modified to yield a more stable product while preserving immunogeni...
|
|
WO/2024/078621A1 |
Disclosed are a nanopore mutant protein and a use thereof. The nanopore mutant protein comprises one or more amino acids of the wild-type PHT nanopore protein as represented by SEQ ID NO: 1 being mutated into other amino acids, or knocko...
|
|
WO/2024/081912A1 |
Disclosed herein include methods, compositions, and kits suitable for use in signal amplification. There are provided, in some embodiments, protease-based signal amplification modules. Disclosed herein include amplifier proteins comprisi...
|
|
WO/2024/080843A1 |
The present application relates to a blood-brain barrier permeable fusion protein and use thereof, and provides: a blood-brain barrier permeable fusion protein comprising an IgG antibody, and a helical region binding moiety of transferri...
|
|
WO/2024/081928A1 |
The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, h...
|
|
WO/2024/078584A1 |
Provided are a method for modifying a capsid protein coding sequence of a cap gene of an adeno-associated virus (AAV), and an AAV capsid protein coding sequence obtained via the method. Additionally provided is the use of a modified AAV ...
|
|
WO/2024/081811A2 |
Disclosed herein are conjugates that can effectively deliver a STING agonist. An example conjugate includes a hydrophilic polymer, a diamidobenzimidazole (diABZI), and a linker attaching the diABZI to the hydrophilic polymer. Also disclo...
|
|
WO/2024/081329A1 |
Provides herein are multifunctional polypeptide molecules comprising T cell receptor variable beta-binding moieties and cytokines and methods of treating conditions or diseases in a subject using the same.
|
|
WO/2024/079449A1 |
The invention relates to a construct and AAV particle comprising a wildtype NDP nucleic acid sequence or a codon-optimised NDP nucleic acid sequence. The invention further relates to products and methods for the treatment of one or more ...
|
|
WO/2024/081871A1 |
Technologies for the prevention and/or treatment of Shigella infections.
|
|
WO/2024/079531A2 |
The application relates to nucleic acid regulatory elements (NAREs) that are able to enhance expression of genes in the liver. The application further relates to methods employing NAREs and uses of the NAREs. Expression cassettes and vec...
|
|
WO/2024/080306A1 |
According to one embodiment of the present invention, it is possible to efficiently produce a highly-active recombinant protein by expressing, in the form of a fusion protein with serum albumin (SA), a physiologically-active protein havi...
|
|
WO/2024/076976A1 |
The disclosure provides polypeptides and polymers, and methods of using the same for reducing the risk of, preventing, or treating inflammation.
|
|
WO/2024/077104A2 |
The present disclosure, at least in part, is based on the discovery of novel anti-Fibroblast activation protein (FAP) antibodies or antigen binding fragments thereof, and genetically modified cells (e.g., iNKT cells) expressing chimeric ...
|
|
WO/2024/074119A1 |
A recombinant collagen and the use thereof in cartilage repair matrix. The recombinant collagen comprises a sequence as shown in SEQ ID No.1; the amino acid sequence of the recombinant collagen comprises N basic repeating units, and the ...
|
|
WO/2024/074571A1 |
Nipah virus (NiV) is a recently emergent, highly pathogenic, zoonotic paramyxovirus. The inventors now designed an anti-CD40 mAb associated either with the Niv G ectodomain protein (Generation-1 vaccine), or the Niv G ectodomain protein ...
|
|
WO/2024/075767A1 |
The purpose of the present invention is to provide: a method for conveniently introducing a gene into a mitochondrion from the outside of a cell; and a method for introducing a nucleic acid having a relatively large size into a mitochond...
|
|
WO/2024/077110A2 |
The present disclosure provides isolated polynucleotides comprising sequences encoding uORF peptides and variants and fragments thereof. The present disclosure also provides constructs and vectors containing the polynucleotides. The pres...
|
|
WO/2024/077256A1 |
The present invention discloses methods and platforms for generating protein binding proteins with specificity for native peptide-MHC (pMHC) complexes. The pMHC binding proteins can be used in bi-specific antibodies or for generating CAR...
|
|
WO/2024/076940A1 |
Nucleic acids are described that encode for triggering receptor expressed on myeloid cells 2 (TREM2) and that can be used in expression constructs, vectors and gene therapies. Also described are methods of using the same for the treatmen...
|
|
WO/2024/077135A1 |
Provided herein are MAGEA1 immunogenic peptides, binding proteins recognizing MAGEA1 immunogenic peptides, and uses thereof.
|
|
WO/2024/075112A1 |
Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for prep...
|
|
WO/2024/075024A1 |
This invention relates to methods for purifying type II collagen from cartilage tissue. The present invention also relates to a type II collagen composition, and the use of the type II collagen composition as a dietary supplement or trea...
|
|
WO/2024/074584A1 |
The present invention relates to stabilized pre-fusion human parainfluenza virus 3 (HPIV3) F protein, and fragments thereof. The invention also relates to nucleic acid molecules encoding such proteins and fragments, and to the use of the...
|
|
WO/2024/076577A1 |
An aqueous formulation includes a PEDF-derived short peptide (PDSP); a blend of PVP/PVA in different ratios around 8/2 – 2/8; and a tonicity agent, which is preferably non-ionic. The PDSP is preferably 14-39 amino acids long and has th...
|
|
WO/2024/075851A1 |
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nu...
|
|
WO/2024/074105A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-4, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/077170A1 |
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primat...
|
|
WO/2023/150771A9 |
Here we developed a COVID-19 vaccine using delta strain spike protein as the antigen to provide a more comprehensive protection against delta strain, and possibly certain degree of protection against other known variants. In combination ...
|
|
WO/2024/076190A1 |
The present invention provides a mutant of adeno-associated virus serotype 1 (AAV1) capsid protein, a nucleic acid encoding the mutant of AAV1 capsid protein, a recombinant AAV1 vector carrying the nucleic acid encoding the mutant of AAV...
|
|
WO/2024/074706A1 |
Disclosed herein are designed ankyrin repeat domain specifically binding to fibroblast activation protein (FAP). Such designed ankyrin repeat domains can be used in recombinant adapter molecules that are displayed on adenoviruses. Adenov...
|
|
WO/2024/077134A1 |
Provided herein are FRAME immunogenic peptides, binding proteins recognizing FRAME immunogenic peptides, and uses thereof.
|
|
WO/2024/076499A2 |
The technology described herein is directed to stromal-free methods of T cell differentiation using a soluble Notch ligand. Also described herein are soluble Notch oligomer complexes and compositions thereof, and methods for making the s...
|
|
WO/2024/077247A1 |
The present disclosure provides compositions and methods useful in the treatment of trinucleotide repeat disorders, including Huntington's disease and Friedreich's ataxia. The present disclosure also provides gRNAs designed to target the...
|
|
WO/2024/077191A1 |
In certain aspects, the disclosure relates to a nucleic acid molecule encoding one or more different thanotransmission polypeptides. Vectors (e.g., engineered viruses, plasmids and transposons), cells and pharmaceutical compositions comp...
|
|
WO/2024/076136A1 |
The present invention relates to a fusion peptide complex comprising a transmembrane domain and use thereof, through which Gram-positive, Gram-negative and multidrug-resistant bacteria can be simultaneously captured in a specimen. Partic...
|
|
WO/2024/074888A2 |
Synthetic apomixis can be achieved in an F1 hybrid of rice by inducing MiMe mutations and egg cell expression of BBM1 in a single step, while simultaneously providing an increased efficiency of clonal seed production. This can be used to...
|
|
WO/2024/077151A1 |
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The ...
|
|
WO/2024/077116A1 |
A pharmaceutical composition for use in promoting bone/cartilage regeneration, includes a PEDF-derived short peptide (PDSP); and mesenchymal stem cells (MSCs). The PDSP is 14-39 amino acids long. The PDSP has the amino-acid sequence sele...
|
|
WO/2024/076121A1 |
The present invention relates to immune cells co-expressing IL-15 and a chimeric antigen receptor comprising an OX40 ligand as an intracellular signaling domain, and to a composition for preventing or treating cancer comprising same as a...
|
|
WO/2023/221936A9 |
Provided are a protein comprising a PD-L1 binding moiety linked to a TGF β binding moiety, an IL-1 binding moiety, an immunostimulating polypeptide (such as soluble LAG3 or soluble CD4) or a CD47 binding moiety, and a pharmaceutical pre...
|
|
WO/2024/076375A1 |
The disclosure provides amino acid sequences (e.g., antibodies) that can bind Glypican 3 Protein (GPC3). The disclosure relates to antigen binding fragments of GPC3 antibodies, conjugates, including immunoconjugates, of GPC3 antibodies, ...
|
|
WO/2024/074142A1 |
Provided are codon-optimized GBA1polynucleotides that encode a GCase protein, with a portion of the coding sequence deviating from the wild-type. Additionally provided are expression constructs, vectors, viral particles, or compositions ...
|
|
WO/2024/073848A1 |
The present disclosure relates to pharmaceutical compositions and methods for the preparation, manufacture and therapeutic use of nucleic acid vaccines comprising lipid nanoparticles (LNP) wherein the LNPs comprise cationic lipids, non-c...
|
|
WO/2024/076237A1 |
The invention relates to a protein comprising at least one ice-binding alpha helix, wherein the ice-binding helix has a twist of less than 100 degrees per residue, preferably a twist of less than 99 degrees per residue, most preferably a...
|
|
WO/2024/077251A2 |
Disclosed are de novo designed polypeptide agonists and antagonists of IL-21, conditionally-active IL-21 agonists and antagonists, and methods for using them to treat cancer or to modulate an immune response.
|
|
WO/2024/074634A1 |
The present disclosure provides RNA technologies for targeting Claudin-18.2 polypeptides. In some embodiments, such RNA technologies can be useful for treatment of diseases associated with positive expression of Claudin-18.2. For example...
|
|
WO/2024/076960A2 |
A vaccine formulation for humans or other mammals (including dogs, horses, and cats) is provided. The vaccine formulation includes two chimeric proteins designed to elicit antibodies that bind to several targets on the surface of Lyme di...
|
|
WO/2024/074713A1 |
The present invention relates to the adoptive therapy using notably CAR-T cells. Here the inventors used a lentiviral vector approach to silence RINF expression in a shRNA- dependent manner and evaluate the consequences of RINF silencing...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
